Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10446325 | 0.84 | PRMT6 (0.56) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 | |
| SCHEMBL4350314 | 0.84 | CYP2A6 (0.68) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 | |
| SCHEMBL3997707 | 0.79 | — | — | |
| SCHEMBL28164029 | 0.78 | CYP2A6 (0.82) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 | |
| SCHEMBL27775798 | 0.77 | HSD17B1 (0.43) | CYP2A6CYP2B6CYP2E1CYP3A4CYP2C9 | |
| SCHEMBL2481528 | 0.75 | KCNH2 (0.57) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 | |
| SCHEMBL879221 | 0.75 | CYP2A6 (0.56) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 | |
| SCHEMBL4442916 | 0.75 | HSD17B1 (0.58) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 | |
| SCHEMBL30285484 | 0.75 | CYP2A6 (0.56) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 | |
| SCHEMBL30172705 | 0.75 | CYP2A6 (0.56) | CYP2A6CYP2B6CYP2E1PRMT6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | claimed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | claimed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | claimed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | claimed |
| US-8349836-B2 | Phthalazine derivatives as inhibitors of protein kinase | ARALDI GIAN-LUCA (US) | 2013-01-08 | — | — | US | disclosed |
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | disclosed |
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | ARALDI GIAN-LUCA | 2011-09-29 | — | — | US | disclosed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | CYP2A6 4344/4885CYP2B6 4415/4885CYP2E1 4351/4885 |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | CYP2A6 4344/4885CYP2B6 4415/4885CYP2E1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.